Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, June 30, 2022.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2022 (2022-06-30): 460.54%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
63.17%
RETURN ON EQUITY (ROE) AVG 3Y
63.17%
RETURN ON EQUITY (ROE) AVG 5Y
63.17%
RETURN ON EQUITY (ROE) AVG 10Y
-102.40%
RETURN ON EQUITY (ROE) AVG 15Y
-102.40%
RETURN ON EQUITY (ROE) AVG 20Y
-93.22%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Agenus Inc.
Market Cap
$311.90M
Return on Equity (ROE)
N/A
TTM Avg
63.17%
3Y Avg
63.17%
5Y Avg
63.17%
Market Cap
$309.19M
Return on Equity (ROE)
-25.73%
TTM Avg
-32.35%
3Y Avg
-2448.72%
5Y Avg
-1749.34%
Market Cap
$318.43M
Return on Equity (ROE)
-41.02%
TTM Avg
-44.84%
3Y Avg
-46.96%
5Y Avg
-38.83%
Market Cap
$321.76M
Return on Equity (ROE)
-403.03%
TTM Avg
-329.00%
3Y Avg
-171.64%
5Y Avg
-130.54%
Market Cap
$322.71M
Return on Equity (ROE)
N/A
TTM Avg
-541.42%
3Y Avg
-296.61%
5Y Avg
-205.57%
Market Cap
$324.76M
Return on Equity (ROE)
-226.56%
TTM Avg
-87.78%
3Y Avg
-55.09%
5Y Avg
-55.09%
Market Cap
$329.37M
Return on Equity (ROE)
-86.10%
TTM Avg
-112.93%
3Y Avg
-76.30%
5Y Avg
-62.48%
Market Cap
$330.19M
Return on Equity (ROE)
-320.77%
TTM Avg
-82.83%
3Y Avg
-78.63%
5Y Avg
-104.90%
Market Cap
$293.30M
Return on Equity (ROE)
-135.62%
TTM Avg
-521.17%
3Y Avg
-307.05%
5Y Avg
43.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agenus Inc. (AGEN) | $311.90M | N/A | 63.17% | 63.17% | 63.17% |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | -25.73% | -32.35% | -2448.72% | -1749.34% |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | -41.02% | -44.84% | -46.96% | -38.83% |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | -403.03% | -329.00% | -171.64% | -130.54% |
| Avita Medical Inc. (RCEL)vs › | $322.71M | N/A | -541.42% | -296.61% | -205.57% |
| CapsoVision, Inc. (CV)vs › | $324.76M | -226.56% | -87.78% | -55.09% | -55.09% |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | -86.10% | -112.93% | -76.30% | -62.48% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | -320.77% | -82.83% | -78.63% | -104.90% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | -135.62% | -521.17% | -307.05% | 43.03% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A | 30.84% | 30.84% | 30.84% |
ROE
N/A
ROA
53.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2022-06-30 | 460.54% |
| 2022-03-31 | -134.39% |
| 2021-12-31 | -76.88% |
| 2021-09-30 | 3.41% |
| 2016-06-30 | -526.33% |
| 2016-03-31 | -227.02% |
| 2015-12-31 | -124.25% |
| 2015-09-30 | -127.64% |
| 2015-06-30 | -106.94% |
| 2015-03-31 | -130.98% |
| 2014-12-31 | -183.37% |
| 2014-09-30 | -45.03% |
| 2014-06-30 | -36.81% |
| 2014-03-31 | -38.87% |
| 2006-03-31 | -443.52% |
| 2005-12-31 | -232.31% |
| 2005-09-30 | -148.27% |
| 2005-06-30 | -112.04% |
| 2005-03-31 | -64.66% |
| 2004-12-31 | -52.76% |
| 2004-09-30 | -46.04% |
| 2004-06-30 | -40.28% |
| 2004-03-31 | -49.01% |
| 2003-12-31 | -62.65% |
| 2003-09-30 | -52.19% |
| 2003-06-30 | -55.05% |
